High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients

Chen, Yuxin; Tong, Xin; Wang, Jian; Huang, Weijin; Yin, Shengxia; Huang, Rui; Yang, Hailong; Chen, Yong; Huang, Aijun; Liu, Yong; Chen, Yan; Yuan, Ling; Yan, Xiaomin; Shen, Han; Wu, Chao

doi:10.1016/j.jinf.2020.05.067

Cited by 210 publications

(254 citation statements)

References 19 publications

(15 reference statements)

Supporting

Mentioning

209

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, seven HCP were exposed to a patient who had a confirmed COVID-19 infection, which has been associated with a higher seroprevalence. 22 As reported very recently, the prevalence of COVID-19 infections in patients with cancer treated at our Department was 0.4% (4/1016). At the time of testing, all four SARS-CoV-2-positive patients were asymptomatic.…”

Section: Discussionsupporting

confidence: 54%

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic

et al. 2020

View full text Add to dashboard Cite

BackgroundDuring the COVID-19 outbreak, healthcare professionals (HCP) are at the frontline of clinical management and at increased risk for infection. The SARS-CoV-2 seroprevalence of oncological HCP and their patients has significant implications for oncological care.MethodsHCP and patients with cancer at the Division of Oncology, Medical University of Vienna were included between 21 March and 4 June and tested for total antibodies against SARS-CoV-2 employing the Roche Elecsys Anti-SARS-CoV-2 immunoassay. Reactive samples were confirmed or disproved by the Abbott SARS-CoV-2 IgG test. Additionally, a structured questionnaire regarding basic demographic parameters, travel history and COVID-19-associated symptoms had to be completed by HCP.Results146 subjects (62 HCP and 84 patients with cancer) were enrolled. In the oncological HCP cohort, 20 (32.3%) subjects were medical oncologists, 28 (45.2%) nurses at our ward and 14 (22.6%) fulfil other functions such as study coordinators. In the patient cohort, most individuals are on active anticancer treatment (96.4%). 26% of the HCP and 6% of the patients had symptoms potentially associated with COVID-19 since the end of February 2020. However, only in 2 (3.2%) HCP and in 3 (3.6%) patients, anti-SARS-Cov-2 total antibodies were detected. The second assay for anti-SARS-Cov-2 IgG antibodies confirmed the positive result in all HCP and in 2 (2.4%) patients, suggesting an initial assay’s unspecific reaction in one case. In individuals with a confirmed test result, an active COVID-19 infection was documented by a positive SARS-CoV-2 RNA PCR test.ConclusionSpecific anti-SARS-CoV-2 antibodies were found solely in persons after a documented SARS-CoV-2 viral infection, thus supporting the test methods’ high sensitivity and specificity. The low prevalence of anti-SARS-CoV-2 antibodies in our cohorts indicates a lack of immunity against SARS-CoV-2. It highlights the need for continued strict safety measures to prevent uncontrolled viral spread among oncological HCPs and patients with cancer.

show abstract

Section: Discussionsupporting

confidence: 54%

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic

et al. 2020

View full text Add to dashboard Cite

show abstract

“…G LOBALLY, SEVERE ACUTE respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced coronavirus disease 2019 (COVID-19) has spread and become a serious public health concern. Because diagnostic testing capacity during the early stage of the COVID-19 pandemic in Japan was limited, and subclinical and asymptomatic COVID-19 cases have existed, 1,2 the accurate prevalence of COVID-19 in Japan remains unclear. Estimation of the accurate prevalence of COVID-19 and its time-dependent changes is clinically important to clarify the viral transmissibility, vaccination requirements, and collective immunity.…”

Section: Introductionmentioning

confidence: 99%

Time‐dependent changes in the seroprevalence of COVID‐19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID‐19

Suda

Ogawa

Kimura

et al. 2020

Hepatology Research

View full text Add to dashboard Cite

Aim: Coronavirus disease 2019 (COVID-19) is a serious public health concern, with unclarified prevalence in Japan. Concomitant liver disease could increase the severity of COVID-19 disease, and chronic liver disease patients sometimes require frequent admission and gastrointestinal endoscopy. Thus, clarifying the prevalence of asymptomatic COVID-19 in outpatients with liver disease is essential for preventing nosocomial infections. We aimed to clarify the time-dependent changes in COVID-19 seroprevalence in liver disease outpatients, who were asymptomatic for COVID-19, in an area of Japan experiencing a second wave of COVID-19. Methods: We included the preserved sera of 100, 300, and 300 consecutive liver disease outpatients, who were asymptomatic for COVID-19, from May 2019, March 2020, and May 2020, respectively. The sera were analyzed immunochromatographically to detect immunoglobulin G against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (KURABO) and by Elecsys Anti-SARS-CoV-2-assay (Roche Diagnostics). Results: Analysis of 100 cases from May 2019, before COVID-19 became pandemic, revealed that the specificity of immunochromatographic tests and Elecsys were 98% (95% confidence interval [CI], 93-99.8%) and 100% (95% CI, 97-100%), respectively. Analysis of 300 cases from March 2020 revealed a seroprevalence of 0.3% (1/300; 95% CI, 0-1.8%) for COVID-19 by Elecsys Anti-SARS-CoV-2 assay. Analysis of 300 cases from May 2020 revealed a seroprevalence of 0% (0/300; 95% CI, 0-1.0%). Conclusions: The Elecsys Anti-SARS-CoV-2 assay has high specificity. The cumulative seroprevalence of COVID-19 by the Elecsys Anti-SARS-CoV-2 assay in outpatients with liver disease in Sapporo, who were asymptomatic for COVID-19, was 0.17% (1/600; 95% CI, 0.0-0.9%) until May 2020.

show abstract

“…In this sense, our data confers to HCWs an IgG seroprevalence of 25.58% (95% IC: 13.52 -41.17). Other studies focused in these professionals reveals rates ranging from 2% 18 , 7.5% 17,20 , 10% [11][12][13] to nearly 20% 19,21 . Our results are in the upper range and backed by recent data from a large cohort of HCWs in a secondary teaching hospital in Madrid province 22 .…”

Section: Discussionmentioning

confidence: 99%

“…A relevant factor to explain the high IgG seroprevalence against SARS-CoV-2 in the studied cohort could be the controlled period of time spent between the end of the symptoms and the test. One of the abovementioned studies was performed among HCWs exposed to COVID-19 patients; these HCWs were under quarantine for 14 days, time when their seroprevalence was analyzed 21 . Interestingly, the seroprevalence was in the highest range among the studies performed in HCWs (17.14%) 21 .…”

Section: Discussionmentioning

confidence: 99%

“…One of the abovementioned studies was performed among HCWs exposed to COVID-19 patients; these HCWs were under quarantine for 14 days, time when their seroprevalence was analyzed 21 . Interestingly, the seroprevalence was in the highest range among the studies performed in HCWs (17.14%) 21 . It could be suggested that this high rate was due to the exposition to con rmed cases, but leaving time enough to develop a robust humoral IgG response 24 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

IgG seroprevalence against SARS-CoV-2 in a cohort of 449 non-hospitalized, high-risk exposure individuals.

Martínez¹,

García²,

Salas³

et al. 2020

Preprint

View full text Add to dashboard Cite

COVID-19 pandemic caused by SARS-CoV-2 led the Spanish government to impose a national lockdown in an attempt to control the spread of the infection. Mobility restrictions but also the requirement of a medical prescription to gain access to serological testing for COVID-19 were included among the measures. Under this scenario, between April 15th to June 15th, 2020, we performed a seroprevalence observational study including 449 individuals that fulfill prescription requirements: manifesting COVID-19 compatible symptoms, being in contact with a COVID-19 confirmed case or belonging to essential occupations including healthcare workers, firefighters or public safety personnel such as police. Importantly, none of the participants was hospitalized. Altogether, we studied this specific, non-commonly addressed cohort for SARS-CoV-2 seroprevalence, uncovering intrinsic features of great demographic interest. The overall rate of IgG seropositivity was 33.69% (95% CI: 29.27 – 38.21). This seroprevalence was comparable between different occupations performed by the participants. However, contacts with confirmed cases associated positively with IgG+ results, with stronger correlation if being a household member. The number of symptoms also correlated positively with IgG+ prevalence. Ageusia/anosmia, pneumonia and cutaneous manifestations were the top-three symptoms that most strongly associated with IgG+ seroprevalence. However, while pneumonia and cutaneous manifestations were barely present in our cohort, fever, ageusia/anosmia and asthenia were the most frequently symptoms described within IgG+ subjects. Therefore, our data illustrate how specific cohorts display heterogeneous characteristics that should be taken into account when identifying population seroprevalence against SARS-CoV-2 and key defining symptoms for COVID-19.

show abstract

High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients

Cited by 210 publications

References 19 publications

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic

Time‐dependent changes in the seroprevalence of COVID‐19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID‐19

IgG seroprevalence against SARS-CoV-2 in a cohort of 449 non-hospitalized, high-risk exposure individuals.

Contact Info

Product

Resources

About